Predicting treatment response and side effects for car-t therapy
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study will look at information from people with non-Hodgkin lymphoma who are getting CAR-T cell therapy (a treatment that uses your own immune cells to attack cancer). The goal is to create tools that help doctors predict how well the treatment will work and what side effects might happen, so they can better care for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a type of blood cancer called non-Hodgkin lymphoma that has come back or hasn't responded to treatment.
- Your doctor has said you are eligible to receive CAR-T cell therapy (a treatment that uses your own immune system cells to attack cancer).
- You agree to take part in the study and allow your health information to be used for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
This study looks at how your immune system responds to CAR-T cell therapy, a treatment that uses your own immune cells to fight certain cancers. By participating, you help researchers learn more about how this therapy affects the body, which could improve care for future patients.
This trial tests a new treatment using your own immune cells, called CAR-T cells, that are modified to find and attack lymphoma cells with CD20 or CD30 markers. It is for people whose lymphoma has not responded to standard treatments or has returned after treatment.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.